Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Etoricoxib Intermediate Market by Type (In-House Manufacturing, Contract Manufacturing Organizations) and by Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis, Chronic Low Back Pain, Acute Pain, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03299

Pages: NA

Charts: NA

Tables: NA

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2. Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.

The growth of the global Etoricoxib market is driven by increase in prevalence of various chronic and acute diseases and surge in geriatric population. Moreover, rise in demand for cost effective anti-inflammatory drugs is anticipated to boost the growth of this market. However, stringent guidelines set by regulating authorities for pharmaceutical products is expected to hinder the market growth.

The global Etoricoxib intermediate market is segmented on the basis of type of manufacturing, indication, and geography. Based on type of manufacturing, it is bifurcated into in-house manufacturing and contract manufacturing organizations. Based on indication, the market is divided into rheumatoid arthritis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Bayer Corporation, Novacap Inc., Abbott Laboratories, Pfizer Inc, Geri-Care Pharmaceuticals, Perrigo Company, Kopran Ltd., Merck Sharp & Dohme Corp., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline, are provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
  • It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

 Key Market Segments

  • By Type
    • In-House Manufacturing
    • Contract Manufacturing Organizations
  • By Indication
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Osteoarthritis
    • Ankylosing Spondylitis
    • Chronic Low Back Pain
    • Acute Pain
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Perrigo Company
  • Novacap Inc.
  • Kopran Ltd.
  • Merck Sharp & Dohme Corp.
  • Abbott Laboratories
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline
  • Pfizer Inc.
  • Geri-Care Pharmaceuticals

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ETORICOXIB INTERMEDIATE MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. In-House Manufacturing

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Contract Manufacturing Organizations

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ETORICOXIB INTERMEDIATE MARKET, BY INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Indication

    • 5.2. Rheumatoid Arthritis

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Psoriatic Arthritis

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Osteoarthritis

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Ankylosing Spondylitis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Chronic Low Back Pain

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Acute Pain

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: ETORICOXIB INTERMEDIATE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Indication

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Etoricoxib Intermediate Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Indication

      • 6.2.6. Canada Etoricoxib Intermediate Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Indication

      • 6.2.7. Mexico Etoricoxib Intermediate Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Indication

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Indication

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Etoricoxib Intermediate Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Indication

      • 6.3.6. Germany Etoricoxib Intermediate Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Indication

      • 6.3.7. Italy Etoricoxib Intermediate Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Indication

      • 6.3.8. Spain Etoricoxib Intermediate Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Indication

      • 6.3.9. UK Etoricoxib Intermediate Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Indication

      • 6.3.10. Russia Etoricoxib Intermediate Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Indication

      • 6.3.11. Rest Of Europe Etoricoxib Intermediate Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Indication

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Indication

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Etoricoxib Intermediate Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Indication

      • 6.4.6. Japan Etoricoxib Intermediate Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Indication

      • 6.4.7. India Etoricoxib Intermediate Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Indication

      • 6.4.8. South Korea Etoricoxib Intermediate Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Indication

      • 6.4.9. Australia Etoricoxib Intermediate Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Indication

      • 6.4.10. Thailand Etoricoxib Intermediate Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Indication

      • 6.4.11. Malaysia Etoricoxib Intermediate Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Indication

      • 6.4.12. Indonesia Etoricoxib Intermediate Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Indication

      • 6.4.13. Rest of Asia Pacific Etoricoxib Intermediate Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Indication

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Indication

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Etoricoxib Intermediate Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Indication

      • 6.5.6. South Africa Etoricoxib Intermediate Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Indication

      • 6.5.7. Saudi Arabia Etoricoxib Intermediate Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Indication

      • 6.5.8. UAE Etoricoxib Intermediate Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Indication

      • 6.5.9. Argentina Etoricoxib Intermediate Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Indication

      • 6.5.10. Rest of LAMEA Etoricoxib Intermediate Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Indication

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Bayer AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novacap Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Abbott Laboratories

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Pfizer Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Geri-Care Pharmaceuticals

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Perrigo Company

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Kopran Ltd.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Merck Sharp And Dohme Corp.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Sun Pharmaceutical Industries Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. GlaxoSmithKline

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ETORICOXIB INTERMEDIATE MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ETORICOXIB INTERMEDIATE MARKET, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR PSORIATIC ARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR OSTEOARTHRITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR ANKYLOSING SPONDYLITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR CHRONIC LOW BACK PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR ACUTE PAIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ETORICOXIB INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ETORICOXIB INTERMEDIATE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA ETORICOXIB INTERMEDIATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 16. U.S. ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 18. CANADA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. CANADA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE ETORICOXIB INTERMEDIATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 29. ITALY ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. ITALY ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 33. UK ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. UK ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC ETORICOXIB INTERMEDIATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 42. CHINA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. CHINA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 46. INDIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. INDIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA ETORICOXIB INTERMEDIATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 69. UAE ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. UAE ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA ETORICOXIB INTERMEDIATE, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA ETORICOXIB INTERMEDIATE, BY INDICATION, 2025-2033 ($MILLION)
  • TABLE 75. BAYER AG: KEY EXECUTIVES
  • TABLE 76. BAYER AG: COMPANY SNAPSHOT
  • TABLE 77. BAYER AG: OPERATING SEGMENTS
  • TABLE 78. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 79. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. NOVACAP INC.: KEY EXECUTIVES
  • TABLE 81. NOVACAP INC.: COMPANY SNAPSHOT
  • TABLE 82. NOVACAP INC.: OPERATING SEGMENTS
  • TABLE 83. NOVACAP INC.: PRODUCT PORTFOLIO
  • TABLE 84. NOVACAP INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 86. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 87. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 88. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 89. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. PFIZER INC.: KEY EXECUTIVES
  • TABLE 91. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 92. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 93. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 94. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. GERI-CARE PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 96. GERI-CARE PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 97. GERI-CARE PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 98. GERI-CARE PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 99. GERI-CARE PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. PERRIGO COMPANY: KEY EXECUTIVES
  • TABLE 101. PERRIGO COMPANY: COMPANY SNAPSHOT
  • TABLE 102. PERRIGO COMPANY: OPERATING SEGMENTS
  • TABLE 103. PERRIGO COMPANY: PRODUCT PORTFOLIO
  • TABLE 104. PERRIGO COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. KOPRAN LTD.: KEY EXECUTIVES
  • TABLE 106. KOPRAN LTD.: COMPANY SNAPSHOT
  • TABLE 107. KOPRAN LTD.: OPERATING SEGMENTS
  • TABLE 108. KOPRAN LTD.: PRODUCT PORTFOLIO
  • TABLE 109. KOPRAN LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. MERCK SHARP AND DOHME CORP.: KEY EXECUTIVES
  • TABLE 111. MERCK SHARP AND DOHME CORP.: COMPANY SNAPSHOT
  • TABLE 112. MERCK SHARP AND DOHME CORP.: OPERATING SEGMENTS
  • TABLE 113. MERCK SHARP AND DOHME CORP.: PRODUCT PORTFOLIO
  • TABLE 114. MERCK SHARP AND DOHME CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 116. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 121. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 122. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 123. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 124. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ETORICOXIB INTERMEDIATE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ETORICOXIB INTERMEDIATE MARKET
  • FIGURE 3. SEGMENTATION ETORICOXIB INTERMEDIATE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ETORICOXIB INTERMEDIATE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALETORICOXIB INTERMEDIATE MARKET
  • FIGURE 11. ETORICOXIB INTERMEDIATE MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. ETORICOXIB INTERMEDIATE MARKET FOR IN-HOUSE MANUFACTURING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ETORICOXIB INTERMEDIATE MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ETORICOXIB INTERMEDIATE MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 15. ETORICOXIB INTERMEDIATE MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ETORICOXIB INTERMEDIATE MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ETORICOXIB INTERMEDIATE MARKET FOR OSTEOARTHRITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ETORICOXIB INTERMEDIATE MARKET FOR ANKYLOSING SPONDYLITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ETORICOXIB INTERMEDIATE MARKET FOR CHRONIC LOW BACK PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ETORICOXIB INTERMEDIATE MARKET FOR ACUTE PAIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ETORICOXIB INTERMEDIATE MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: ETORICOXIB INTERMEDIATE MARKET
  • FIGURE 28. TOP PLAYER POSITIONING, 2024
  • FIGURE 29. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. NOVACAP INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. NOVACAP INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. NOVACAP INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. GERI-CARE PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. GERI-CARE PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. GERI-CARE PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. PERRIGO COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. PERRIGO COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. PERRIGO COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. KOPRAN LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. KOPRAN LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. KOPRAN LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. MERCK SHARP AND DOHME CORP.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. MERCK SHARP AND DOHME CORP.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. GLAXOSMITHKLINE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Etoricoxib Intermediate Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved